BGT
BIOGENETEC FPO [BGT]
Healthcare · ASX Small Cap
$0.0330 +0.0%
Updated 2026-03-02 · Scores refresh every scan
⚠ Funding Risk — Cash runway under 4 quarters. Capital raise or funding may be required.
Appeared in 2 consecutive scans→ Score +9First seen: 2026-02-25
Score Breakdown
Technical58
Catalyst50
Sentiment50
Fundamental41
Momentum63
Risk Gate27
Active Signals
Bullish Signals
- Bollinger squeeze (breakout building)
- Price above MAs (uptrend)
- Sustained volume spike (5.5x median) on DOWN trend
- Volatility contracting (breakout setup)
- Above 200-day MA (long-term uptrend)
- Critical cash runway (1.7 quarters)
- 4C filed 2026-01-29
- Strong revenue growth (+208%)
- Micro-cap ($5-20M) - high risk
- CANSLIM S: Tight float (35%)
- Strong revenue momentum (+208%)
- Altman Z-Score in distress zone (1.11 < 1.81)
- Low-priced stock risk ($0.033)
- ASX200 bullish (+1.5% 5d)
- RBA cutting (+2pts)
Risk Signals
- MACD momentum weakening
- Insufficient sentiment data (defaulting to neutral)
- Neutral/mixed sentiment
Recent Catalysts
NONE Appendix 4D and Half-Year Accounts 31 December 2025
NONE Flavocide Acute Neurotoxicity Study Underway
NONE Flavocide Reproductive Toxicity Study Underway
LOW Quarterly Activities/Appendix 4C Cash Flow Report
Recent ASX Announcements
| 2026-02-23 | Appendix 4D and Half-Year Accounts 31 December 2025 PRICE SENSITIVE |
| 2026-02-12 | Flavocide Acute Neurotoxicity Study Underway |
| 2026-02-08 | Flavocide Reproductive Toxicity Study Underway |
| 2026-02-01 | CFO and Company Secretary Appointment/Resignation |
| 2026-01-29 | Quarterly Activities/Appendix 4C Cash Flow Report PRICE SENSITIVE |
Key Metrics
$10.1M
Market Cap
29K
Avg Volume
5.5x
Vol Ratio
$0.02 — $0.06
52-Week Range
N/A
Short Interest
2 qtrs
Cash Runway
-202.2%
ROE
N/A
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | pass | Float: 35% |
| L | Leader vs Laggard | pass | RS: 6 |
| I | Institutional Sponsorship | insufficient_data | Inst: 0% |
| M | Market Direction | pass | Bullish |
Sector: Healthcare
Ranked #68 of 119 · Sector avg: 51
View all Healthcare signals →